/PRNewswire/ Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter.
LAVAL, QC and CAMBRIDGE, England, Sept. 1, 2022 /PRNewswire/ Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that it received confirmation
Termination results in anticipated cash savings of $33.1 millionRemoves last of legacy contracts associated with former plasma-derived therapeutics businessLAVAL, QC and CAMBRIDGE, ENGLAND,
$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras developmentNet loss from continuing operations of $6.5 million during the quarter ended June 30, 2022
Liminal BioSciences Inc : Liminal BioSciences Announces Discontinuation of Fezagepras Development finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.